AR100403A1 - Derivados de pirazina - Google Patents
Derivados de pirazinaInfo
- Publication number
- AR100403A1 AR100403A1 ARP150101453A ARP150101453A AR100403A1 AR 100403 A1 AR100403 A1 AR 100403A1 AR P150101453 A ARP150101453 A AR P150101453A AR P150101453 A ARP150101453 A AR P150101453A AR 100403 A1 AR100403 A1 AR 100403A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- alkyl
- hydrogen atom
- atom
- alkoxy
- Prior art date
Links
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 10
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 7
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 6
- 125000005843 halogen group Chemical group 0.000 abstract 6
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 abstract 4
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 4
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 abstract 3
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 abstract 3
- 125000006619 (C1-C6) dialkylamino group Chemical group 0.000 abstract 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 abstract 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 abstract 2
- 125000004448 alkyl carbonyl group Chemical group 0.000 abstract 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000004739 (C1-C6) alkylsulfonyl group Chemical group 0.000 abstract 1
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 abstract 1
- 125000004414 alkyl thio group Chemical group 0.000 abstract 1
- 125000005530 alkylenedioxy group Chemical group 0.000 abstract 1
- 125000003277 amino group Chemical group 0.000 abstract 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 abstract 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 150000003216 pyrazines Chemical class 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 125000004434 sulfur atom Chemical group 0.000 abstract 1
- 125000003831 tetrazolyl group Chemical group 0.000 abstract 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Liquid Crystal Substances (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2014099677 | 2014-05-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR100403A1 true AR100403A1 (es) | 2016-10-05 |
Family
ID=54479954
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP150101453A AR100403A1 (es) | 2014-05-13 | 2015-05-12 | Derivados de pirazina |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US9856237B2 (enExample) |
| EP (1) | EP3144306B1 (enExample) |
| JP (1) | JP6173576B2 (enExample) |
| KR (1) | KR20170004998A (enExample) |
| CN (1) | CN106458998A (enExample) |
| AR (1) | AR100403A1 (enExample) |
| AU (1) | AU2015260300A1 (enExample) |
| CA (1) | CA2948797A1 (enExample) |
| CY (1) | CY1119876T1 (enExample) |
| DK (1) | DK3144306T3 (enExample) |
| ES (1) | ES2654434T3 (enExample) |
| HR (1) | HRP20180122T1 (enExample) |
| HU (1) | HUE035728T2 (enExample) |
| IL (1) | IL248900A0 (enExample) |
| LT (1) | LT3144306T (enExample) |
| ME (1) | ME02978B (enExample) |
| MX (1) | MX2016014693A (enExample) |
| NO (1) | NO3144306T3 (enExample) |
| PH (1) | PH12016502223A1 (enExample) |
| PL (1) | PL3144306T3 (enExample) |
| PT (1) | PT3144306T (enExample) |
| RS (1) | RS56837B1 (enExample) |
| RU (1) | RU2016148735A (enExample) |
| SG (1) | SG11201609359WA (enExample) |
| SI (1) | SI3144306T1 (enExample) |
| SM (1) | SMT201800155T1 (enExample) |
| TW (1) | TW201609702A (enExample) |
| WO (1) | WO2015174417A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111943957B (zh) * | 2019-05-17 | 2023-01-06 | 中国医学科学院药物研究所 | 喹啉甲酰胺类化合物及其制备方法和用途 |
| CN116496198A (zh) * | 2023-06-26 | 2023-07-28 | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | 一种4-羟基-2'-(1-苄基-5-硝基吡咯甲叉)-苯甲酰肼衍生物及其制备方法和应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998034922A1 (en) * | 1997-02-05 | 1998-08-13 | Sankyo Company, Limited | Prophylactic or therapeutic agent for diabetic complication |
| JP4397875B2 (ja) * | 1997-02-05 | 2010-01-13 | 第一三共株式会社 | 糖尿病合併症予防薬又は治療薬 |
| CN101012193A (zh) * | 2003-01-02 | 2007-08-08 | 霍夫曼-拉罗奇有限公司 | 新cb 1受体反激动剂 |
| JP2007145786A (ja) * | 2005-11-30 | 2007-06-14 | Toray Ind Inc | ピラジン誘導体及びそれを有効成分とする腎炎治療薬 |
| JP5378988B2 (ja) | 2007-04-11 | 2013-12-25 | キッセイ薬品工業株式会社 | ５員環へテロ環誘導体及びその医薬用途 |
| AR081930A1 (es) | 2010-06-16 | 2012-10-31 | Ardea Biosciences Inc | Compuestos de tioacetato |
| KR20150082194A (ko) | 2012-11-14 | 2015-07-15 | 데이진 화-마 가부시키가이샤 | 피리딘 유도체 |
-
2015
- 2015-05-12 NO NO15792266A patent/NO3144306T3/no unknown
- 2015-05-12 CA CA2948797A patent/CA2948797A1/en not_active Abandoned
- 2015-05-12 TW TW104115028A patent/TW201609702A/zh unknown
- 2015-05-12 CN CN201580024718.7A patent/CN106458998A/zh active Pending
- 2015-05-12 LT LTEP15792266.7T patent/LT3144306T/lt unknown
- 2015-05-12 SM SM20180155T patent/SMT201800155T1/it unknown
- 2015-05-12 US US15/310,337 patent/US9856237B2/en not_active Expired - Fee Related
- 2015-05-12 PL PL15792266T patent/PL3144306T3/pl unknown
- 2015-05-12 RS RS20180019A patent/RS56837B1/sr unknown
- 2015-05-12 JP JP2016519266A patent/JP6173576B2/ja not_active Expired - Fee Related
- 2015-05-12 EP EP15792266.7A patent/EP3144306B1/en active Active
- 2015-05-12 SG SG11201609359WA patent/SG11201609359WA/en unknown
- 2015-05-12 MX MX2016014693A patent/MX2016014693A/es unknown
- 2015-05-12 PT PT157922667T patent/PT3144306T/pt unknown
- 2015-05-12 AU AU2015260300A patent/AU2015260300A1/en not_active Abandoned
- 2015-05-12 ME MEP-2018-5A patent/ME02978B/me unknown
- 2015-05-12 DK DK15792266.7T patent/DK3144306T3/en active
- 2015-05-12 HR HRP20180122TT patent/HRP20180122T1/hr unknown
- 2015-05-12 ES ES15792266.7T patent/ES2654434T3/es active Active
- 2015-05-12 KR KR1020167031523A patent/KR20170004998A/ko not_active Withdrawn
- 2015-05-12 SI SI201530130T patent/SI3144306T1/en unknown
- 2015-05-12 RU RU2016148735A patent/RU2016148735A/ru not_active Application Discontinuation
- 2015-05-12 HU HUE15792266A patent/HUE035728T2/en unknown
- 2015-05-12 WO PCT/JP2015/063654 patent/WO2015174417A1/ja not_active Ceased
- 2015-05-12 AR ARP150101453A patent/AR100403A1/es unknown
-
2016
- 2016-11-09 PH PH12016502223A patent/PH12016502223A1/en unknown
- 2016-11-10 IL IL248900A patent/IL248900A0/en unknown
-
2018
- 2018-02-01 CY CY20181100126T patent/CY1119876T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20170004998A (ko) | 2017-01-11 |
| IL248900A0 (en) | 2017-01-31 |
| EP3144306B1 (en) | 2017-11-15 |
| ME02978B (me) | 2018-10-20 |
| PL3144306T3 (pl) | 2018-04-30 |
| WO2015174417A1 (ja) | 2015-11-19 |
| AU2015260300A1 (en) | 2016-12-22 |
| SG11201609359WA (en) | 2016-12-29 |
| PT3144306T (pt) | 2018-01-08 |
| HUE035728T2 (en) | 2018-05-28 |
| JP6173576B2 (ja) | 2017-08-02 |
| JPWO2015174417A1 (ja) | 2017-04-20 |
| MX2016014693A (es) | 2017-02-23 |
| US9856237B2 (en) | 2018-01-02 |
| EP3144306A1 (en) | 2017-03-22 |
| EP3144306A4 (en) | 2017-03-22 |
| CA2948797A1 (en) | 2015-11-19 |
| LT3144306T (lt) | 2018-01-10 |
| PH12016502223A1 (en) | 2017-02-06 |
| DK3144306T3 (en) | 2018-01-02 |
| TW201609702A (zh) | 2016-03-16 |
| RS56837B1 (sr) | 2018-04-30 |
| CN106458998A (zh) | 2017-02-22 |
| HRP20180122T1 (hr) | 2018-02-23 |
| SI3144306T1 (en) | 2018-02-28 |
| ES2654434T3 (es) | 2018-02-13 |
| CY1119876T1 (el) | 2018-06-27 |
| RU2016148735A (ru) | 2018-06-19 |
| RU2016148735A3 (enExample) | 2018-06-19 |
| SMT201800155T1 (it) | 2018-05-02 |
| US20170152242A1 (en) | 2017-06-01 |
| NO3144306T3 (enExample) | 2018-04-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020011745A (es) | Terapias genicas para los trastornos lisosomales. | |
| CY1124097T1 (el) | Κρυσταλλικο πολυμορφο της ελευθερης βασης της 2-υδροξυ-6-((2-(1-ισοπροπυλο-1η-πυραζολ-5-υλο)πυριδιν-3-υλο)μεθοξυ)βενζαλδεϋδης | |
| AR103561A1 (es) | Fenilpiridinas herbicidas | |
| AR099824A1 (es) | Compuestos bicíclicos | |
| AR095781A1 (es) | Inhibidores de proteínas de quinasa | |
| AR112797A1 (es) | Inhibidores de kras g12c y métodos para utilizarlos | |
| DK3169671T3 (da) | 1-(5-(tert.-butyl)isoxazol-3-yl)-3-(4-((phenyl)ethynyl)phenyl)ureaderivater og relaterede forbindelser som flt3-inhibitorer til behandling af kræft | |
| JOP20210274A1 (ar) | طرق لإعطاء مثبط vmat2 معين | |
| CR20120643A (es) | Derivados de imidazopiridina, su procedimiento de preparaciòn y su aplicaciòn en terapèutica | |
| AR093468A1 (es) | Derivados de piridina | |
| DOP2015000270A (es) | Potenciador de inhibidores del homólogo de zeste | |
| AR103297A1 (es) | Pirrolo y pirazolopirimidinas como inhibidores de la proteasa 7 específica de ubiquitina | |
| AR093364A1 (es) | Imidazo[1,2-a]piridincarboxamidas aminosustituidas y su uso | |
| AR106301A1 (es) | Composiciones de pirrolpirimidina como inhibidores de quinasas | |
| EA201790395A1 (ru) | Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы | |
| MX2016015565A (es) | Ciertos inhibidores de la proteina quinasa. | |
| AR100886A1 (es) | 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas | |
| UY36654A (es) | Azabenzimidazoles con propiedades moduladoras del receptor ampa y composiciones farmacéuticas que los contienen | |
| AR092347A1 (es) | Derivados de azaindol | |
| AR101815A1 (es) | Compuestos y composiciones como inhibidores de quinasa | |
| AR100940A1 (es) | Derivados de 1,2,4-triazoles plaguicidas, y sus intermediarios, composiciones y sus procesos relacionados | |
| AR083903A1 (es) | Derivados de benzooxazol y benzotiazol sulfonamidas, utiles para tratar trastornos del ritmo cardiaco y cancer, composiciones farmaceuticas que los contienen y metodo para prepararlos | |
| MX2018010025A (es) | Derivados de quinazolindion-6-carbonilo y su utilizacion como herbicidas. | |
| PH12018501181A1 (en) | Phenyl derivatives as cannabinoid receptor 2 agonists | |
| AR104856A1 (es) | Derivados de difluorocetamida |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |